CeriBell is a medical technology company that has built a point-of-care EEG platform designed to make brain-wave monitoring as simple and as fast as a fingerstick, and the June quarter shows the platform hitting commercial escape velocity. The system combines disposable headbands, a pocket-sized recorder and proprietary AI algorithms to detect seizures and delirium at the bedside, and the company has now crossed the seven-hundred-hospital adoption mark and is pushing into the roughly six thousand acute-care facilities it estimates could benefit from the technology. The thesis is that CeriBell becomes the standard of care for EEG in the acute setting, replacing the cart-based conventional systems that have bottlenecked seizure diagnosis in hospital emergency rooms and intensive care units.
The financial story is a medtech classic: revenue ramping fast, gross margins already strong, and operating losses widening as the company pours every dollar of gross profit back into sales coverage and research. Total revenue reached twenty-eight point one million dollars in the quarter, up thirty-three percent year-over-year, and the six-month figure of fifty-four point six million represents a thirty-one percent year-over-year gain. Gross margin held at roughly ninety-two percent - the AI software plus disposable headband business carries a software-like margin profile - but operating loss expanded to twenty million as the sales force grew forty percent.
The recent regulatory cadence is the catalyst that should compound revenue. The company received a new FDA clearance in June 2026 for two neurology algorithms, an FDA-cleared delirium monitoring system in late 2025, and clearance on the full next-generation hardware platform. The forward question is whether the hospital sales cycle keeps shortening as the new clearances and the seven-hundred-hospital installed base combine to push CeriBell past the inflection point where adoption becomes self-sustaining.